Elizabeth Berry-Kravis MD, Ph.D. is a Professor of Pediatrics, Neurological Sciences, and Biochemistry at Rush University Medical Center in Chicago.  She attended the University of Notre Dame for undergraduate studies and the University of Chicago for her MD/Ph.D. and training in Pediatric Neurology. She moved to Rush in 1992 and established the Fragile X Clinic and Research Program, through which she provides care to over 700 patients with fragile X syndrome (FXS). She has studied medical issues, epilepsy and psychopharmacology in FXS, and has been a leader in translational research in FXS including development of outcome measures/biomarkers, natural history studies, newborn screening, and particularly clinical trials of new targeted treatments. Her laboratory studies cellular roles of fragile X mental retardation protein (FMRP), relationship to phenotypes, and optimization of genetic testing methods.

In the past decade she has expanded clinical translational work to other neurodevelopmental disorders and genetic neurodegenerative diseases including autism spectrum disorders, Phelan McDermid syndrome, Rett syndrome, Angelman syndrome, Smith-Magenis syndrome, DDX3X syndrome, Niemann-Pick type C, Battens disease, pantothenate kinase-associated neuro-degeneration, and creatine transporter deficiency. She has over 250 publications on genetic neurological diseases and is on Advisory/Review Boards for the FRAXA Research Foundation, National Fragile X Foundation, Phelan McDermid Syndrome Foundation, Rettsyndrome.org, Angelman Syndrome Foundation, Foundation for Angelman Syndrome Therapeutics and GATHER Foundation. She has received the NFXF Jarrett Cole Clinical Award, FRAXA Champion Award, NFXF William and Enid Rosen Research Award, March of Dimes Jonas Salk Research Award, American Academy of Neurology Sidney Carter Award in Child Neurology, John Merck Fund Sparkplug Award, FRAXA Ingenuity Award, and Child Neurology Society Denckla Award for her work in treatment translation for FXS and genetic cognitive disorders.

Dr. David A. Jett is a Program Director at National Institute of Neurological Disorders and Stroke (NINDS).

He leads the Office of Neural Exposome and Toxicology (ONETOX) and leads a new thrust at NINDS on the exposomic factors in neurological disease and disorders.  Dr. Jett is the Director of the NIH Countermeasures Against Chemical Threats (CounterACT) Program, a program supported by a specific Congressional appropriation to the NIH for the development of new drugs and diagnostic tools for treating victims of chemical exposures during an emergency.  He also serves as Scientific Team Leader within the Division of Translational Research at NINDS.  After receiving a Ph.D. in Neuropharmacology and Toxicology at the University of Maryland School of Medicine, Dr. Jett conducted post-doctoral research and subsequently joined the faculty at Johns Hopkins University's Bloomberg School of Public Health where he conducted research as a university professor for several years.  He has expertise and experience with pesticides and nerve agents. Dr. Jett has authored many scientific articles and book chapters in the area of neurotoxicology and has chaired sessions and given keynote addresses at many national and international scientific meetings. He holds the position of Professor Adjunct of Chronic Disease and Epidemiology within the Yale School of Public Health. Dr. Jett has served on White House and intergovernmental committees that set the nation's research priorities, as well as science advisory panels for the Environmental Protection Agency and the Department of Defense. Dr. Jett's other major long-term interest is training and programs designed to increase diversity in the neuroscience research workforce.

Dr. Aditya Joshi earned his MD at the University of Pittsburgh School of Medicine, after receiving an S.B. in Brain and Cognitive Science and an S.B. in Physics from the Massachusetts Institute of Technology. He completed residency in neurology, fellowship in epilepsy, and fellowship in clinical neurophysiology (focusing on intraoperative monitoring) at Stanford Hospital and Clinics, and is now an Assistant Professor of Clinical Neurology at the University of Pennsylvania. While at Stanford, Dr. Joshi participated in the Stanford Biodesign Innovation course, and was a member of the first Short Course in Adaptive Neurotechnologies held by the NIH-funded National Center for Adaptive Neurotechnologies. He is currently a member of the ASENT Annual Meeting Program Committee. He is very interested in the application of medical devices that utilize electromagnetic fields to interact with the body for the diagnosis and treatment of medically refractory epilepsy and other neurological disorders.

Director, UCSF Pediatric Epilepsy Center of Excellence
Co-Director, PISCES Longitudinal Integrated Clerkship
San Francisco, California

Joseph E. Sullivan, MD, is a professor of neurology and pediatrics at the University of California, San Francisco (UCSF) and director of the UCSF Pediatric Epilepsy Center of Excellence at Benioff Children’s Hospital. A graduate of Union College and Albany Medical College, he completed a pediatric residency at the Ann & Robert H. Lurie Children’s Memorial Hospital of Northwestern University in Chicago, where he spent an additional year as pediatric chief resident.  He then completed his neurology, child neurology and epilepsy training at the Hospital of the University of Pennsylvania and at The Children’s Hospital of Philadelphia, both in Philadelphia, before taking his first faculty position at UCSF in 2007 where he currently serves as director of the Pediatric Epilespy Center and has served as a principal investigator for a number of clinical trials in the rare pediatric epilepsies.